CLSN Celsion Corp.

Celsion Corporation to Hold Third Quarter 2018 Financial Results Conference Call on Thursday, November 15, 2018

Celsion Corporation to Hold Third Quarter 2018 Financial Results Conference Call on Thursday, November 15, 2018

LAWRENCEVILLE, N.J, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended September 30, 2018 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. ET on Thursday, November 15, 2018. To participate in the call, interested parties may dial 1-877-260-1479 (Toll-Free/North America) or 1-334-323-0522 (International/Toll) and ask for the Celsion Corporation 3rd Quarter 2018 Earnings Call (Conference Code: 6704591) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live over the internet at

The call will be archived for replay on Thursday, November 15, 2018 and will remain available until Thursday, November 29, 2018. The replay can be accessed at 1-888-203-1112 (Toll-Free/North America) or 1-719-457-0820 (International/Toll) using Conference Code: 6704591. An audio replay of the call will also be available on the Company’s website, , for 90 days after 2:00 p.m. ET on Thursday, November 15, 2018.

About Celsion Corporation

Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer. The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: . (CLSN-FIN).

Investor Contact

Argot Partners

Sam Martin

212-600-1902

EN
08/11/2018

Underlying

CLSNCelsion Corp.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Celsion Corp.

 PRESS RELEASE
Free
CLSN CELSION CORP.

IMUNON Reports Interim Progression-Free Survival and Overall Survival ...

IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer Intent-to-treat population shows 9-month OS improvement over control arm Subgroup of patients treated with IMNN-001 + PARPi shows meaningful PFS and OS trend compared with control arm Continued follow-up is indicated to confirm initial observations LAWRENCEVILLE, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapies and next-generation vaccines, announces int...

September 28, 2023 1 EN
 PRESS RELEASE
Free
CLSN CELSION CORP.

IMUNON Releases Enterprise Video Highlighting the Company’s Mission, V...

IMUNON Releases Enterprise Video Highlighting the Company’s Mission, Vision, Values, Breakthroughs and Technologies Provides a look at the new manufacturing facility in Huntsville, Alabama Introduced as part of IMUNON's newly relaunched website LAWRENCEVILLE, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, today announced the release of an enterprise video that highlights the company’s mission, vision, values, breakthroughs and technolog...

September 26, 2023 1 EN
 PRESS RELEASE
Free
CLSN CELSION CORP.

IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ...

IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, reminds investors of its virtual R&D Day event tomorrow, September 14th beginning at 4:00 p.m. Eastern time. There is no need to pre-register for the event. A live and archived webcast will be available in th...

September 13, 2023 1 EN
 PRESS RELEASE
Free
CLSN CELSION CORP.

IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m...

IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET Program will feature members of IMUNON executive management along with key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that it will hold a virtual R&D Day event on September 14th beginning at 4:00 p.m. Eastern time. Details about speakers and instructions on how to participate are below. ...

September 7, 2023 1 EN
 PRESS RELEASE
Free
CLSN CELSION CORP.

IMUNON to Participate in the H.C. Wainwright Global Investment Confere...

IMUNON to Participate in the H.C. Wainwright Global Investment Conference LAWRENCEVILLE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announces that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. A webcast of the IMUNON presentation will be available on the section of the Company’s website beginning Monday, September 11 at 7:00 a.m. Eastern time. Management is available throughout the conference for virtual one-on-one meetings. Institutional inv...

September 5, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch